Preclinical antitumor efficacy of analogs of XK469: Sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate

Investigational New Drugs

Volumn 16, Issue 2, 1998, Pages 129-139

  Corbett, Thomas H ^a,c   LoRusso, Patricia ^a   Demchick, Lisa ^a   Simpson, Chiab ^a   Pugh, Susan ^a   White, Kathryn ^a   Kushner, Juiwanna ^a   Polin, Lisa ^a   Meyer, Jennifer ^a   Czarnecki, Jennifer ^a   Heilbrun, Lance ^a   Horwitz, Jerome P ^a   Gross, Janet L ^b   Behrens, Carl H ^b   Harrison, Barbara A ^b   McRipley, Ron J ^b   Trainor, George ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUPONT COMPANY   (United States)

^c KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Antitumor; Preclinical; XK469 analog

Indexed keywords

ANTINEOPLASTIC AGENT; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG; XK 469;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; LEUKEMIA L 1210; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; MALE; MICE; MOLECULAR STRUCTURE; QUINOXALINES;

EID: 7844224757     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006174622061     Document Type: Article

References (32)

1. Branda RF, McCormack JJ, Perlmutter CA: Cellular pharmacology of chloroquinoxaline sulfonamide and a related compound in murine B16 melanoma cells. Biochem Pharmacol 37: 4557-4564, 1988
2. Branda RF, Moore AL, McCormack JJ: Immunosuppressive properties of chloroquinoxaline sulfonamide. Biochem Pharmacol 38: 3521-3526, 1989
3. Rigas JR, Francis PA, Miller VA et al.: Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule. Cancer Chemother Pharmacol 35(6): 483-488, 1995
4. Conley BA, O'Hara S, Wu S et al.: Phase I trial of chloroquinoxaline sulfonamide with correlation of its pharmacokinetics and pharmacodynamics. Cancer Chemother Pharmacol 37: 139-149, 1995
5. Miller VA, Rigas JR, Tong WP et al.: Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancer. Cancer Chemother Pharmacol 40(4): 415-418, 1997
6. Craciunescu et al.: An R Acad Farm 51: 653-658, 1985
7. Foster et al.: Invest New Drugs 3: 401-410, 1985
8. Katagiri K, Yoshida T, Sato K: Quinoxaline antibiotics. In: Antibiotics, Vol III, Mechanism of Action of Antimicrobial and Antitumor Agents. Corcorn and Hahn (eds), Springer-Verlag, pp 234-251, 1974
9. Piatti SE, Bekerman D, Gaozza CH: Sintesis de Derivados de bis-quinoxalina con posible actividad antineoplasica. Anales de Quimica, Ser. C 82: 85-89, 1986
10. Piatti SE, Nuber N, Krotz L, Gaozza CH: Sintesis de Derivados de Bisaminoquinoxalina. Ensayos de Interaction con adn y de citotoxicidad. Anales de Quimica 85: 105-109, 1989
11. Zegar I, Graslund A, Bergman J, Eriksson M, Norden B: Interaction of ellipticine and a Indolo [2,3b]-quinoxaline derivative with DNA and synthetic polynucleotides. Chem Biol Interactions 72: 277-293, 1989
12. Fawzi, US Patent 4,609,396; Ura et al., US Patent 4,629,493; Serban et al., US Patent 4,803,273; Serban et al., US Patent 4,655,819; Serban et al., EP 0,023,785 A2; Davis et al., EP 0,323,727 A2.
13. Fawzi, US Patent 4,609,396; Ura et al., US Patent 4,629,493; Serban et al., US Patent 4,803,273; Serban et al., US Patent 4,655,819; Serban et al., EP 0,023,785 A2; Davis et al., EP 0,323,727 A2.
14. Fawzi, US Patent 4,609,396; Ura et al., US Patent 4,629,493; Serban et al., US Patent 4,803,273; Serban et al., US Patent 4,655,819; Serban et al., EP 0,023,785 A2; Davis et al., EP 0,323,727 A2.
15. Fawzi, US Patent 4,609,396; Ura et al., US Patent 4,629,493; Serban et al., US Patent 4,803,273; Serban et al., US Patent 4,655,819; Serban et al., EP 0,023,785 A2; Davis et al., EP 0,323,727 A2.
16. Fawzi, US Patent 4,609,396; Ura et al., US Patent 4,629,493; Serban et al., US Patent 4,803,273; Serban et al., US Patent 4,655,819; Serban et al., EP 0,023,785 A2; Davis et al., EP 0,323,727 A2.
17. Fawzi, US Patent 4,609,396; Ura et al., US Patent 4,629,493; Serban et al., US Patent 4,803,273; Serban et al., US Patent 4,655,819; Serban et al., EP 0,023,785 A2; Davis et al., EP 0,323,727 A2.
18. LoRusso PM, Demchik L, Knight J, Polin L, Behrens CH, McRipley R, Gross JL, Harrison BA, Corbett TH: Preclinical antitumor activity of XK469. EORTC 104,1994
19. LoRusso PM, Demchik L, Knight J, Polin L, Behrens CH, McRipley R, Gross JL, Harrison BA, Corbett TH: Preclinical Antitumor Activity of XK469. Proc. of AACR 35: 401, 1994
20. Corbett T, Valeriote F, LoRusso P et al.: Tumor models and the discovery and secondary evaluation of solid tumor active agents. Intern J Pharmacognosy (Supp) 33: 102-122, 1995
21. Corbett TH, Leopold WR, Dykes DJ, Roberts BJ, Griswold Jr DP, Schabel Jr FM: Toxicity and anticancer activity of a new triazine antifolate (NSC-127755). Cancer Res 42: 1707-1715, 1982
22. Corbett TH, Roberts BJ, Trader MW, Laster Jr WR, Griswold Jr DP, Schabel Jr FM: Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agents. Cancer Treat Rep 66(5): 1187-1200, 1982
23. Corbett T, Valeriote F, Baker L: Is the P388 murine tumor nolonger adequate as a drug discovery model? Invest New Drugs 5: 3-20, 1987
24. Corbett TH, Valeriote FA: Rodent Models in Experimental Chemotherapy. In: The Use of Rodent Tumors in Experimental Cancer Therapy: Conclusions and Recommendations, R.F. Kallman (ed) Pergamon Press, Chapt. 50, pp 233-247, 1987
25. Corbett TH, Valeriote FA, Polin L et al.: Discovery of Solid Tumor Active Agents Using a Soft-Agar-Colony-Formation Disk-Diffusion-Assay. In: Cytotoxic Anticancer Drags: Models and Concepts for Drug Discovery and Development. FA Valeriote, TH Corbett, LH Baker (eds), Kluwer Academic Publishers, pp 33-87, Boston/Dordrecht/London, 1992
26. Corbett T, Valeriote F, LoRusso P et al.: In Vivo Methods for Screening and Preclinical Testing; Use of rodent solid tumors for drug discovery. In: The Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval. B Teicher (ed), Humana Press Inc., Totowa, NJ Chapt-5, pp 75-99, 1997
27. Corbett TH, Griswold Jr DP, Roberts BJ, Peckham JC, Schabel Jr FM: Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 35: 2434-2439, 1975
28. Corbett TH, Griswold Jr DP, Roberts BJ, Peckham JC, Schabel Jr FM: Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer 40(5): 2660-2680, 1977
29. Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold Jr DP, Schabel Jr FM: Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57B1/6 mice. Cancer Res 44: 717-726, 1984
30. Corbett TH: A selective two-tumor soft agar assay for drug discovery. AACR, Abst. No. 1289, 25: 325, 1984
31. Corbett T, Valeriote F, Baker L et al.: Antitumor activity of N-[[1-[[2-(Diethylamino)ethyl]amino]-9-oxo-9H-Thioxanthen-4-yl]methyl] metanesulfonamide (WIN33377) and analogs: Expert Opinion on Investigational Drugs 3(12): 1281-1292, 1994
32. Corbett TH, Valeriote FA, Demchik L, Polin L, Panchapor C, Pugh S, White K, Kushner J, Jones J, Jones L, Foster B, Wiegand R, Lisow L, Golakoti T, Heltzel C, Ogino J, Patterson G, Moore R: Preclinical anticancer activity of cryptophycin-8. J Exper Therap Oncol 1: 95-108, 1996